Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Internal Medicine | Rheumatology | Conference News

Back to Journal Articles

ACR: Rituximab Found Helpful for ANCA-Associated Vasculitis

Last Updated: October 19, 2009.

 

Head-to-head trial shows the drug is as effective as standard therapy with cyclophosphamide

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In patients with severe ANCA-associated vasculitis, treatment with rituximab may be as effective as standard treatment with cyclophosphamide, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting, held from Oct. 17 to 21 in Philadelphia.

MONDAY, Oct. 19 (HealthDay News) -- In patients with severe ANCA-associated vasculitis, treatment with rituximab may be as effective as standard treatment with cyclophosphamide, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting, held from Oct. 17 to 21 in Philadelphia.

John H. Stone, M.D., of Massachusetts General Hospital in Boston, and colleagues randomly assigned 197 patients with severe Wegener's granulomatosis or microscopic polyangiitis to receive either rituximab or cyclophosphamide.

The researchers found that the primary outcome achievement of remission was similar in the rituximab and cyclophosphamide groups (64 versus 55 percent). They also found that a similar proportion of rituximab and cyclophosphamide patients achieved a Birmingham Vasculitis Activity Score for Wegener's granulomatosis of zero and a prednisone dose less than 10 mg/day at six months (71 versus 62 percent). Furthermore, no significant group differences were observed in disease flares or adverse events.

"These results provide strong support for the use of rituximab as an alternative to cyclophosphamide in ANCA-associated vasculitis," the authors conclude.

Several authors of the study reported financial relationships with medical and pharmaceutical companies.

Abstract

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Drugs to Treat Bowel Disease Linked to Lymphomas Next: Review Discusses Brachial Plexus Birth Palsy Procedure

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.